GLP-1 Analogues for Weight Loss: Benefits and Risks on World Obesity Day 2026

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

World Obesity Day 2026: GLP-1 Analogues for Weight Loss? Know the Risks

GLP-1 analogues like semaglutide and tirzepatide mirror gut hormones to regulate appetite, insulin, and satiety. (Picture: Canva)

M

Moneycontrol•03-03-2026, 13:28

World Obesity Day 2026: GLP-1 Analogues for Weight Loss? Know the Risks

•World Obesity Day on March 4 highlights obesity as a complex, chronic disease affecting over a billion people globally, linking to multiple health problems.
•Dr. Pooja U.K. emphasizes that while lifestyle changes are core, medical science offers transformative therapies like GLP-1 analogues for those for whom lifestyle changes alone are insufficient.
•GLP-1 analogues (semaglutide, tirzepatide) mimic gut hormones, regulating appetite and insulin, showing 14-20% weight loss and improved blood sugar control in trials.
•Newer triple agonists like retatrutide show even greater promise, with nearly 29% weight reduction and improved metabolic markers.
•These powerful prescription therapies require full medical assessment, evaluation of risk factors, and crucial monitoring; experimental trends like 'microdosing' are risky.

Read Full Article on Moneycontrol in English

✦

More like this

✦

More like this

GLP-1 weight-loss drugs like Mounjaro and semaglutide are booming, but experts continue to stress on lifestyle changes for lasting results. (Image: Getty)

GLP-1 Drugs: Experts Uncover Truth Behind Popular Weight Loss Injections

A regular meal-time routine helps the body manage blood glucose levels more efficiently.

Skipping Meals for Weight Loss? Doctors Warn of Blood Sugar Spikes

The report highlights that adoption readiness is significantly higher among informed consumers. Among diabetics aware of GLP-1 therapies, 49.2 percent indicate likelihood to use them, and 44.1 percent express preference for weekly dosage formats.

India's Obesity Crisis: 73 Million Overweight, Yet GLP-1 Awareness Below 5%

A simple 48-hour oat-based diet reduced LDL cholesterol by 10% in people with metabolic syndrome (Photo: Pexels)

Oatmeal Power: 48 Hours, 10% Bad Cholesterol Drop, Study Reveals

The 'skinny pen' revolution is not a passing trend but a permanent shift in how humanity manages metabolic disease. (Representational image/X)

Weight-Loss Jabs: UK's Walk-In Model Sparks Debate, India Faces Regulatory Challenge

Mounjaro, launched in March 2025, garnered a cumulative revenue of Rs 233 crore till September 25 and Rs 80 crore turnover in the month of September.

Weight Loss Drugs: Hype, Hope, or Health Hazard? Unpacking the Reality in India